MaxCyte Inc (MXCT) concluded trading on Thursday at a closing price of $2.61, with 0.47 million shares of worth about $1.23 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -30.95% during that period and on April 17, 2025 the price saw a gain of about 2.35%. Currently the company’s common shares owned by public are about 105.71M shares, out of which, 97.69M shares are available for trading.
Stock saw a price change of 11.54% in past 5 days and over the past one month there was a price change of -20.18%. Year-to-date (YTD), MXCT shares are showing a performance of -37.26% which decreased to -34.59% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.21 but also hit the highest price of $5.26 during that period. The average intraday trading volume for MaxCyte Inc shares is 637.87K. The stock is currently trading -2.58% below its 20-day simple moving average (SMA20), while that difference is down -20.18% for SMA50 and it goes to -32.86% lower than SMA200.
MaxCyte Inc (NASDAQ: MXCT) currently have 105.71M outstanding shares and institutions hold larger chunk of about 71.48% of that.
The stock has a current market capitalization of $276.73M. It has posted earnings per share of -$0.39 in the same period. It has Quick Ratio of 10.32 while making debt-to-equity ratio of 0.09. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MXCT, volatility over the week remained 10.23% while standing at 8.55% over the month.
Analysts are in expectations that MaxCyte Inc (MXCT) stock would likely to be making an EPS of -0.1 in the current quarter, while forecast for next quarter EPS is -0.09 and it is -0.31 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.12 which is -0.09 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.09 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 10.51% while it is estimated to increase by 11.99% in next year. EPS is likely to grow at an annualized rate of 7.37% for next 5-years, compared to annual growth of -11.37% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Craig Hallum on November 29, 2023 offering a Buy rating for the stock and assigned a target price of $7 to it. On August 24, 2021, William Blair Initiated their recommendations, while on August 24, 2021, Wedbush Initiated their ratings for the stock with a price target of $36. Stock get a Buy rating from Stifel on August 24, 2021.
